Sion, Switzerland

Rosa Gobbi

This inventor holds 1 USPTO granted patent. Top assignee: Eureon Ag. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rosa Gobbi. Retrieved from https://idiyas.com/inventor/rosa-gobbi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Rosa Gobbi: Innovator in Therapeutic Agents

Introduction

Rosa Gobbi is a notable inventor based in Sion, Switzerland. She has made significant contributions to the field of medicine, particularly in the development of therapeutic agents. Her work focuses on innovative solutions for treating complex health conditions.

Latest Patents

Rosa Gobbi holds 1 patent for her invention titled "Therapeutical agent useful for the treatment of plasma cell neoplasias." This patent specifically addresses the use of calcium trifluoroacetate for the preparation of a drug aimed at treating plasma cell neoplasias, with a particular emphasis on multiple myeloma.

Career Highlights

Throughout her career, Rosa has demonstrated a commitment to advancing medical science. Her work at Eureon AG has positioned her as a key player in the development of new therapeutic strategies. She has been instrumental in researching and formulating innovative treatments that address critical health challenges.

Collaborations

Due to space constraints, the details of her collaborations will not be included.

Conclusion

Rosa Gobbi's contributions to the field of therapeutic agents highlight her dedication to improving patient outcomes through innovative research. Her work continues to inspire advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…